This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
PRI-724
DrugBank Accession Number
DB15034
Background

PRI-724 is under investigation in clinical trial NCT03620474 (Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 658.652
Monoisotopic: 658.230484489
Chemical Formula
C33H35N6O7P
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
43Y934BBZ6
CAS number
1198780-38-9
InChI Key
VHOZWHQPEJGPCC-AZXNYEMZSA-N
InChI
InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31-/m0/s1
IUPAC Name
(4-{[(6S,9S,9aS)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-[(quinolin-8-yl)methyl]-octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl]methyl}phenoxy)phosphonic acid
SMILES
C[C@H]1[C@H]2N([C@@H](CC3=CC=C(OP(O)(O)=O)C=C3)C(=O)N1CC1=CC=CC3=C1N=CC=C3)C(=O)CN(C)N2C(=O)NCC1=CC=CC=C1

References

General References
Not Available
ChemSpider
64854018

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentColorectal Adenocarcinoma (CRC) / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
1Active Not RecruitingTreatmentPrimary Bilary Cirrhosis (PBC) / Primary Biliary Cholangitis1
1CompletedTreatmentAdenocarcinomas of the Pancreas / Advanced Pancreatic Cancer / Pancreatic Metastatic Cancer1
1CompletedTreatmentHepatitis C Virus-infected Cirrhosis1
1RecruitingTreatmentCirrhosis of the Liver1
1TerminatedTreatmentSolid Tumors, Advanced Solid Tumors1
1, 2Active Not RecruitingTreatmentCirrhosis of the Liver / Hepatitis C Virus (HCV) Infection / Viral Hepatitis B1
1, 2CompletedTreatmentAcute Myeloid Leukemia (AML) / Leukemia Chronic Myelogenous Leukemia (CML)1
Not AvailableCompletedNot AvailableHepatitis C Virus-infected Cirrhosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00634 mg/mLALOGPS
logP2.09ALOGPS
logP0.44ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)1.81ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area155.85 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity171.76 m3·mol-1ChemAxon
Polarizability65.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:44 / Updated at June 12, 2020 16:53